Synapse - Robert Motzer

Results (1247)

Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma

Journal Article

Gleeson, J. P.; Nikolovski, I.; Dinatale, R.; Zucker, M.; Knezevic, A.; Patil, S.; Ged, Y.; Kotecha, R. R.; Shapnik, N.; Murray, S.; more...
Clinical Cancer Research (2021)

Fulltext@MSK | Save

Single-cell sequencing links multiregional immune landscapes and tissue-resident T cells in ccRCC to tumor topology and therapy efficacy

Journal Article

Krishna, C.; DiNatale, R. G.; Kuo, F.; Srivastava, R. M.; Vuong, L.; Chowell, D.; Gupta, S.; Vanderbilt, C.; Purohit, T. A.; Liu, M.; more...
Cancer Cell (2021)

Fulltext@MSK | Save

Evaluation of germline genetic testing criteria in early-onset kidney cancer

Meeting Abstract

Truong, H.; Sheikh, R.; Kotecha, R.; Kemel, Y.; Khurram, A.; Reisz, P.; Lenis, A. T.; Joseph, V.; Mandelker, D.; Lee, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy and safety of avelumab plus axitinib (A plus Ax) versus sunitinib (S) in elderly patients with advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Uemura, H.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Patterns of progression in patients treated with nivolumab plus ipilimumab (NIVO plus IPI) versus sunitinib (SUN) for first-line treatment of advanced renal cell carcinoma (aRCC) in CheckMate 214

Meeting Abstract

Tannir, N. M.; Motzer, R. J.; Albiges, L.; Plimack, E. R.; George, S.; Powles, T.; Donskov, F.; Rini, B. I.; Grunwald, V.; Hammers, H. J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Efficacy of avelumab plus axitinib (A plus Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101

Meeting Abstract

Tomita, Y.; Motzer, R. J.; Choueiri, T. K.; Rini, B. I.; Miyake, H.; Oya, M.; Albiges, L.; Fujii, Y.; Umeyama, Y.; Wang, J.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT)

Meeting Abstract

Rappold, P. M.; Silagy, A. W.; Kuo, F.; Marker, M.; Reising, A.; Millholland, J.; Russo, P.; Coleman, J.; Voss, M. H.; Chan, T. A.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Nivolumab plus cabozantinib (NIVO plus CABO) versus sunitinib (SUN) for advanced renal cell carcinoma (aRCC): Outcomes by sarcomatoid histology and updated trial results with extended follow-up of CheckMate 9ER

Meeting Abstract

Motzer, R. J.; Choueiri, T. K.; Powles, T.; Burotto, M.; Bourlon, M. T.; Hsieh, J. J.; Maruzzo, M.; Shah, A. Y.; Suarez, C.; Barrios, C. H.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase III study evaluating efficacy and safety of MK-6482 + lenvatinib versus cabozantinib for second- or third-line therapy in patients with advanced renal cell carcinoma (RCC) who progressed after prior anti-PD-1/L1 therapy

Meeting Abstract

Motzer, R. J.; Liu, Y.; Perini, R. F.; Zhang, Y.; Heng, D. Y. C.
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save

Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study)

Meeting Abstract

Motzer, R. J.; Porta, C.; Eto, M.; Powles, T.; Grunwald, V.; Hutson, T. E.; Alekseev, B.; Rha, S. Y.; Kopyltsov, E.; Vidal, M. J. M.; more...
Journal of Clinical Oncology (2021)

Fulltext@MSK | Save